Next-Generation Amylin Weight-Loss Drugs Near Approval as CagriSema Awaits FDA Decision
Start here
A new wave of amylin-based obesity medicines is moving toward the market. At EASD 2026, CagriSema, Novo Nordisk's combination of cagrilintide and semaglutide, showed 22.4% weight loss over 52 weeks versus placebo (p<0.0001), and Lilly presented Phase IIb data for its amylin analogue eloralintide. Novo Nordisk submitted CagriSema's NDA to the FDA in December 2025, with a decision expected in Q4 2026. Eloralintide's path is less settled: higher-dose combinations with tirzepatide showed elevated dropout rates in the Phase IIb trial, and observers are split over whether this reflects tolerability problems or overly fast titration. Lilly has not disclosed the reasons for the dropouts, leaving the molecule's dose strategy an open question.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- reddit.comPickThe Next Generation of Weight-Loss Drugs Is Almost Here
A Reddit thread on r/GLP1ResearchTalk debates next-generation amylin-based weight-loss drugs presented at EASD 2026, where CagriSema (cagrilintide plus semaglutide) showed 22.4% weight loss over 52 weeks versus placebo (p<0.0001) and Lilly reported Phase IIb data for its amylin analogue eloralintide. Commenters split over whether high dropout rates in higher-dose eloralintide plus tirzepatide combinations signal tolerability problems, with others blaming faster titration; Lilly has not disclosed dropout reasons. Novo Nordisk submitted CagriSema's NDA to the FDA in December 2025, with a decision expected in Q4 2026.
Heat trend for this story
Not enough continuous observation yet to draw a trend.